Phase Ib of Cyclophosphamide, Pomalidomide, Dexamethasone and Daratumumab (CPD-DARA) in patients with relapsed/refractory multiple myeloma. (The CPD-DARA Study).

2024-516945-37-00 Protocol CTRIAL-IE 19-17 Human pharmacology (Phase I) - Bioequivalence study Ended

Start 4 Nov 2021 · End 9 Sep 2025 · Status Ended · 1 EU/EEA countries · 3 sites · Protocol CTRIAL-IE 19-17

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Bioequivalence study
Status Ended
Participants planned 16
Countries 1
Sites 3

Relapsed/ refractory multiple myeloma

Key facts

Sponsor
Cancer Trials Ireland
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
4 Nov 2021 → 9 Sep 2025
Decision date (initial)
2024-10-29
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2024-516945-37-00
EudraCT number
2019-004386-40
ClinicalTrials.gov
NCT04667663

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Relapsed/ refractory multiple myeloma

VersionLevelCodeTermSystem organ class
21.0 LLT 10028228 Multiple myeloma 10029104
20.0 SOC 10029104 Neoplasms benign malignant and unspecified (incl cysts and polyps) 2

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Cancer Trials Ireland

Sponsor organisation
Cancer Trials Ireland
Address
Rcsi House, 121 Saint Stephen's Green 121 Saint Stephen's Green
City
Dublin 2
Postcode
D02 H903
Country
Ireland

Scientific contact point

Organisation
Cancer Trials Ireland
Contact name
Chief Operations Officer

Public contact point

Organisation
Cancer Trials Ireland
Contact name
Chief Operations Officer

Locations

1 EU/EEA country · 3 investigational sites

By country

CountryMS statusPlanned subjectsSites
Ireland Ended 16 3
Rest of world 0

Investigational sites

Ireland

3 sites · Ended
University Hospital Galway
Haematology, Newcastle Road, H91 YR71, Galway
Cork University Hospital
Haematology, Wilton, T12 DC4A, Cork
Beaumont Hospital
Haematology, Beaumont Road, Beaumont, Dublin 9

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Ireland 2021-11-04 2025-09-09 2021-11-23 2023-05-23

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-09-25 Ireland Acceptable
2024-10-29
2024-10-29
2 SUBSTANTIAL MODIFICATION SM-1 2025-05-13 Ireland Acceptable
2025-08-18
2025-08-18